More News! 6 Feb 2019
British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy
Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs for neurological diseases such as…
Heptares Therapeutics
- Latest Posts
News and Trends 5 Oct 2017
British Biotech Founder Receives the Nobel Prize in Chemistry 2017
Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This…
News and Trends 1 Sep 2017
Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal
Allergan's partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer's disease.…
Interview 17 Jul 2017
Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares
Heptares is expanding into a range of indications with its GPCR platform. I caught up with CSO & co-founder Fiona…
ADVERTISEMENT
In Depth 6 Jun 2017
A Painful Case: How Biotech is trying to Break Through in Analgesia
Just 2% of experimental pain treatments clear Phase II. Why is this challenge so great, and which biotechs are gunning…
News and Trends 18 May 2017
Heptares receives €4.5M Milestone for New Migraine Drug Candidate
The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches.…
News and Trends 27 Apr 2017
Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation
Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects.…
News and Trends 5 Apr 2017
Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor
Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares…
Best in Biotech 15 Mar 2017
What are the Best Countries to Recruit Biotech Talents in 2017?
Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look…
News and Trends 31 Jan 2017
New British Biotech-Academia Alliance takes on Cardiovascular Disease
Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based…
ADVERTISEMENT
News and Trends 26 Dec 2016
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash…
News and Trends 30 Nov 2016
Drugging the Undruggable: New Acquisition to Boost GPCR Drugs
Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in…
News and Trends 23 Nov 2016
These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’
GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear…
News and Trends 10 May 2016
Life Sciences VC gets €204M in its Biggest Fundraiser Ever
MVM Capital has raised its fourth and largest funding round. It now has an additional €204M to invest in healthcare…
News and Trends 7 Apr 2016
Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech
Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer's, to Allergan for up to…
News and Trends 29 Mar 2016
Interviewing the Managing Director of the $750M Venture Fund of Novartis
This is last interview you will see from SACHS in Zurich. I met with Markus Goebel, the managing director of…
ADVERTISEMENT
News and Trends 17 Mar 2016
A Relief for Migraines at last? The Biotech race for the Ultimate Cure
A Migraine is more than just a headache; it is a neurological disorder affecting a staggering 10% of the worldwide…
News and Trends 30 Nov 2015
Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal
Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for their G-protein receptor platform. Heptares…
News and Trends 10 Aug 2015
A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response
Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire…
News and Trends 31 Jul 2015
MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs
Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance…
